{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:32:55Z","timestamp":1789237975482,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":4212,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/modpathol.2011.48","type":"journal-article","created":{"date-parts":[[2011,3,18]],"date-time":"2011-03-18T11:17:52Z","timestamp":1300447072000},"page":"974-982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas"],"prefix":"10.1016","volume":"24","author":[{"given":"Dora","family":"Dias-Santagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bergethon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A John","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rakheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai P","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2011.48_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/000348940411300314","article-title":"Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma: need for a clinical trial?","volume":"113","author":"Schroder","year":"2004","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1038\/modpathol.2011.48_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0560.2006.00570.x","article-title":"Metastatic hidradenocarcinoma with demonstration of Her-2\/neu gene amplification by fluorescence in situ hybridization: potential treatment implications","volume":"34","author":"Nash","year":"2007","journal-title":"J Cutan Pathol"},{"key":"10.1038\/modpathol.2011.48_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1468-3083.2009.03301.x","article-title":"Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma","volume":"24","author":"Battistella","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/modpathol.2011.48_bib4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/1097-0142(19940315)73:6<1631::AID-CNCR2820730615>3.0.CO;2-7","article-title":"Clear cell eccrine carcinomas of the skin: a clinicopathologic study of nine patients","volume":"73","author":"Wong","year":"1994","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2011.48_bib5","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.48_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.48_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.48_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2006.05.023","article-title":"HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosinase kinase inhibitors","volume":"10","author":"Wang","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2011.48_bib9","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"10.1038\/modpathol.2011.48_bib10","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1097\/JTO.0b013e318174e96e","article-title":"Second-generation epidermal growth factor receptor tyrosinase kinase inhibitors in non-small cell lung cancer","volume":"3","author":"Riely","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1038\/modpathol.2011.48_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/modpathol.2011.48_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.yexmp.2008.03.010","article-title":"Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology","volume":"85","author":"Holden","year":"2008","journal-title":"Exp Mol Pathol"},{"key":"10.1038\/modpathol.2011.48_bib13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":"Clinical responses observed with imatinib or sorafenib in melanoma patients expression mutations in KIT","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2011.48_bib14","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.48_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","article-title":"Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine","volume":"2","author":"Dias-Santagata","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1038\/modpathol.2011.48_bib16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1600-0560.2007.00935.x","article-title":"Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma","volume":"35","author":"Janisson-Dargaud","year":"2008","journal-title":"J Cutan Pathol"},{"key":"10.1038\/modpathol.2011.48_bib17","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous\/mucosal type","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2011.48_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2008.07.038","article-title":"Decreased survival in EGFR gene amplified vulvar carcinoma","volume":"111","author":"Growdon","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.48_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer","volume":"18","author":"Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1038\/modpathol.2011.48_bib20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","article-title":"The PIK3CA gene is mutated with high frequency in human breast cancers","volume":"3","author":"Bachman","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/modpathol.2011.48_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature06914","article-title":"Translating insights from the cancer genome into clinical practice","volume":"452","author":"Chin","year":"2008","journal-title":"Nature"},{"key":"10.1038\/modpathol.2011.48_bib22","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1158\/1078-0432.CCR-10-1201","article-title":"PIKing the right patient","volume":"169","author":"Turke","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2011.48_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-6656","article-title":"Mutations in the phophatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitot PX-866 whereas oncogenic Ras is a dominant predictor for resistance","volume":"69","author":"Ihle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2011.48_bib24","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2011.48_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/PDM.0b013e31818e5fa4","article-title":"PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases","volume":"18","author":"Michelucci","year":"2009","journal-title":"Diagn Mol Pathol"},{"key":"10.1038\/modpathol.2011.48_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/humu.9316","article-title":"PIK3CA mutations in advanced ovarian carcinomas","volume":"25","author":"Wang","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1038\/modpathol.2011.48_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1038\/modpathol.2011.48_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W","article-title":"TP53myc gene alterations independently predict poor prognosis in breast cancer patients","volume":"16","author":"Berns","year":"1996","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/modpathol.2011.48_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00666204","article-title":"The P53 tumor suppressor genes in breast cancer","volume":"32","author":"Elledge","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/modpathol.2011.48_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancer","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1038\/modpathol.2011.48_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1038\/modpathol.2011.48_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<317::AID-IJC5>3.0.CO;2-Y","article-title":"p53 mutations in sweat gland carcinomas","volume":"76","author":"Biernat","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1038\/modpathol.2011.48_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0560.2000.027001030.x","article-title":"Genetic changes in sweat gland carcinomas","volume":"27","author":"Takata","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1038\/modpathol.2011.48_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0046-8177(98)90234-9","article-title":"A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation","volume":"29","author":"Takata","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2011.48_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/DAD.0b013e3181984f10","article-title":"Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2\/neu gene expression\/amplification, TP53 gene mutation analysis, and t(11;19) translocation","volume":"31","author":"Kazakov","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1038\/modpathol.2011.48_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1054\/bjoc.2000.1530","article-title":"Germline TP53 alterations in Finish breast cancer families are rare and occur at conserved mutation-prone sites","volume":"84","author":"Rapakko","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2011.48_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jmg.2009.073429","article-title":"TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes","volume":"47","author":"Ruijs","year":"2010","journal-title":"J Med Genet"},{"key":"10.1038\/modpathol.2011.48_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<169::AID-PATH408>3.0.CO;2-P","article-title":"Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast","volume":"189","author":"Kuenen-Boumeester","year":"1999","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2011.48_bib39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/DAD.0b013e3181cd64f2","article-title":"Epidermal growth factor receptor gene status by fluorescent in situ hybridization in malignant, atypical, and benign hidradenomas","volume":"32","author":"Piris","year":"2010","journal-title":"Am J Dermatopathol"},{"issue":"Suppl 4","key":"10.1038\/modpathol.2011.48_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1038\/modpathol.2011.48_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2008.182","article-title":"Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method","volume":"22","author":"Gupta","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2011.48_bib42","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.48_bib43","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/cncr.22593","article-title":"Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer","volume":"109","author":"Sone","year":"2007","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2011.48_bib44","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/labinvest.3700077","article-title":"Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of EGFR amplifications despite protein overexpression in invasive breast carcinoma","volume":"84","author":"Kersting","year":"2004","journal-title":"Lab Invest"},{"key":"10.1038\/modpathol.2011.48_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-0597-3","article-title":"KIT (CD-117)-positive breast cancers are infrequent and lack KIT gene mutations","volume":"10","author":"Simon","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2011.48_bib46","first-page":"956","article-title":"KIT protein expression and analysis of c-kit mutation in adenoid cystic carcinoma","volume":"12","author":"Holst","year":"1999","journal-title":"Mod Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol201148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201148","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222028484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222028484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:05:27Z","timestamp":1760231127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222028484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0893395222028484"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2011.48","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2011.48","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}